Home Tools
Log in
Cart

Search Result

Search Results for " castration-resistant prostate cancer "

20

Compounds

Cat No. Product Name Synonyms Targets
T22263 Bavdegalutamide ARV-110 Androgen Receptor
Bavdegalutamide (ARV-110) is a PROTAC degrader of androgen receptor (AR). Bavdegalutamide can be used in studies about prostate cancer. Bavdegalutamide shows oral activity and selectivity and facilitates the ubiquitinati...
T8217 Enzalutamide carboxylic acid Androgen Receptor , Drug Metabolite
Enzalutamide carboxylic acid is an antagonist of androgen receptor (AR) .
T0380 Bicalutamide ICI-176334 Androgen Receptor , Autophagy
Bicalutamide (ICI-176334), a synthetic, nonsteroidal antiandrogen, competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens.
T6889 MI-136 Apoptosis , Epigenetic Reader Domain , Androgen Receptor
MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced.
T9246 JNJ-63576253 Androgen Receptor
JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
T36841 IPI-9119 Fatty Acid Synthase
IPI-9119 is an orally active, selective and irreversible FASN inhibitor (IC50 = 0.3 nM).
T8933 JNJ-63576253 free base TRC253,JNJ-63576253 Androgen Receptor
JNJ-63576253 free base (TRC253) is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 can be used for the re...
T2895 Lupeol Fagarasterol,Monogynol B,Clerodol,(3β,13ξ)-Lup-20(29)-en-3-ol,Farganasterol Apoptosis , Androgen Receptor , Akt
Lupeol (Monogynol B) is a novel androgen receptor inhibitor with anti-inflammatory and antioxidant activity.
TQ0214 Dimethylcurcumin ASC-J9,GO-Y025 Androgen Receptor
Dimethylcurcumin (ASC-J9) (ASC-J9) is an androgen receptor degradation enhancer. It effectively suppresses castration-resistant prostate cancer cell proliferation and invasion.
T2543 Cabazitaxel XRP6258,RPR-116258A,TXD 258,taxoid XRP6258 Microtubule Associated , Autophagy
Cabazitaxel (taxoid XRP6258) is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel.
T6215 Abiraterone Acetate Zytiga,CB7630 P450
Abiraterone Acetate (CB7630) is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
T8497 SX-682 CXCR
SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.
T13363 Y06137 Epigenetic Reader Domain , PKC
Y06137 is an effective and selective BET inhibitor with a Kd of 81 nM for BRD4(1) bromodomain. Y06137 can be used for research on the treatment of castration-resistant prostate cancer.
T76758 Rilotumumab AMG 102 c-Met/HGFR
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (...
T76743 Emibetuzumab LY2875358 c-Met/HGFR
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study adv...
T7752 (S,R,S)-AHPC-Me VHL ligand 2,E3 ligase Ligand 1A Ligand for E3 Ligase
(S,R,S)-AHPC-Me (E3 ligase Ligand 1A) (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein[1]. (S,R,S)-AHPC-Me can be used to synthesize ARV-771. ARV-771 is a...
T61109 HG122
HG122 is a chemical compound that effectively facilitates the degradation of androgen receptor (AR) via the proteasome pathway, leading to the inhibition of castration-resistant prostate cancer.
T69874 LLS30
LLS30 is an allosteric inhibitor of Galectin-1 (Gal-1). LLS30 decreases Gal-1 binding affinity to its binding partners, and potentially overcomes metastatic castration-resistant prostate cancer (mCRPC).
T17930 EC1167 Others
EC1169 is a targeted tubulysin conjugate that utilizes EC1167 as its linker. This compound shows promise in the treatment of recurrent metastatic, castration-resistant prostate cancer (MCRPC)[1].
T75058 RLA-5331
RLA-5331 is an anti-androgen compound with iron-activating properties, demonstrating anti-proliferative effects on the metastatic castration-resistant prostate cancer (mCRPC) cell line [1].
1 2
TargetMol